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 Stress-induced hyperglycemia is common in critically ill patients, but there is 
uncertainty about what constitutes an optimal blood glucose target range for 
glycemic control. Furthermore, to reduce the rate of hyperglycemic and 
hypoglycemic events, model-based glycemic control protocols have been 
introduced, such as the stochastic targeted (STAR) glycemic control 
protocol. This protocol has been used in the intensive care units of 
Christchurch and Gyulà Hospital since 2010, and in Malaysia since 2017. In 
this study, we analyzed the adaptability of the protocol and identified the 
blood glucose target range most favorable for use in the Malaysian 
population. Virtual simulation results are presented for two clinical cohorts: 
one receiving treatment by the STAR protocol itself and the other receiving 
intensive insulin therapy by the sliding scale method. Performance and safety 
were analyzed using five clinical target ranges, and best control was 
simulated at a target range of 6.0–10.0 mmol/L. This target range had the 
best balance of performance, with the lowest risk of hypoglycemia and the 
lowest requirement for nursing interventions. The result is encouraging as the 
STAR protocol is suitable to provide better and safer glycemic control while 
using a target range that is already widely used in Malaysian intensive care 
units. 
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1. INTRODUCTION 
In 2001, a randomized controlled trial reported that significant reduction in mortality could be 
achieved through glycemic control compared with that using conventional insulin therapy [1]. Improved 
control was achieved with a lower and stricter blood glucose (BG) target range of 4.4–6.1 mmol/L (80–110 
mg/dL) compared with that obtained with the conventional range of <10.0–11.1 mmol/L (180–200 mg/dL). 
These findings changed the standard of intensive care worldwide. However, subsequent randomized 
controlled trials targeting similar BG ranges have shown no benefits with respect to mortality, but a 
significantly increased risk of hypoglycemia [2-4]. In the NICE-SUGAR study, the largest multi-center study 
to date [4], a BG target of <10.0 mmol/L effectively lowered mortality compared with that obtained with the 
strict target range of 4.5–6.0 mmol/L (81–108 mg/dL). These benchmark results again changed clinical 
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choice; however, this time, it was toward a wider and slightly higher target range [5], [6] that aimed to 
control hyperglycemia while reducing the risk of hypoglycemia. 
Glycemic control requires frequent measurements of BG level as well as estimates of recommended 
insulin doses, which are based on an adopted protocol that heavily relies on a BG target range. To obtain 
glycemic control that is both better (less risk of hyperglycemia) and safer (less risk of hypoglycemia), 
computerized protocols have been recommended for use to provide the recommended insulin dose and BG 
measurement interval [7]. Although a growing number of intensive care units (ICUs) are starting to use 
validated computer algorithms with beneficial effects on glycemic control [e.g., EndoTool, LOGIC, Gluco-
Space and stochastic targeted (STAR)] [8-13], such tools are not yet widely implemented in clinical practice. 
The clinically validated STAR glycemic control protocol uses model-based insulin sensitivity (SI) [14, 15] to 
characterize and forecast per-patient changes in metabolic state. 
The STAR protocol is not only patient-specific but also flexible. This protocol has been used in the 
intensive care units of Christchurch and Gyulà Hospital since 2010, and in Malaysia since 2017 [16]. The 
clinical target ranges and maximum risk (BG <4.0/4.4 mmol/L) can be set by the clinical staff, and the model 
selects treatments that are justified by their predicted effects on the full range of possible BG outcomes. Its 
default target range is 4.4–8.0 mmol/L (80–145 mg/dL), with a 5% risk of hypoglycemia. These values are 
based on the trial on the Christchurch and Gyulà cohort [17] and correspond to the best performance with 
their skewed distribution and patient demographics. Figure 1 presents the results of a data collection in which 
fellow Malaysian collaborators aimed to identify the default clinical target ranges implemented in Malaysian 
ICUs glycemic control. The figure shows the number of Malaysian hospitals ICU (both government and 
research universities) according to their BG target ranges used with the sliding scale method. In total, 24, 11, 
4, and 3 hospitals use target ranges of 6.0–10.0, 6.0–8.0, 4.0–6.0, and 8.0–10.0 mmol/L. Other target ranges 
are only used by single hospitals, based on expert judgment. Three of the four target ranges stated above 
require strict control within the range of 2.0 mmol/L. 
 
 
 
 
Figure 1. The composition chart of the number of hospitals in Malaysia practicing different glycemic control 
target range 
 
 
The main aim of this study was to extend the advantages of the SI and STAR virtual trial framework 
[18, 19] to Malaysian patients, based on assessments of the safety and performance of different target ranges. 
Second, we used the STAR virtual trial to identify the favorable BG target range for glycemic control in 
critically ill patients in a Malaysian cohort. 
 
 
2. METHODS 
2.1.   Study Design 
Clinical data of ICU patients from two hospitals were used for this study. These were the 
International Islamic University Malaysia Medical Centre (IIUM) and the Hospital Tengku Ampuan Afzan 
(HTAA), which are both based in Kuantan, Malaysia. The ethics committees of IIUM and HTAA granted 
approval for the analysis and publication of these data. Both sets of data for critically ill patients were 
considered as different cohorts and were then analyzed together and separately using the same virtual patient 
generation method. Five simulations were performed using the virtual patient data, using STAR protocol, and 
with the following target ranges: 4.4–8.0, 4.0–6.0, 6.0–8.0, 6.0–10.0, and 8.0–10.0 mmol/L. 
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2.2.   Physiological Model and Virtual Patients 
The model used to create virtual patients was the clinically validated Intensive Control Insulin-
Nutrition-Glucose (ICING) model [14, 15]. This model consists of seven mathematical equations to 
determine the following: BG level, interstitial insulin level, plasma insulin level, gut and stomach glucose 
levels, enteral glucose input, and endogenous insulin production. Details of this model and its equations are 
available in [19]. With the exception of model-based insulin sensitivity , which was measured hourly using 
the integral-based fitting method [20], all parameters were identified and finalized based on the data obtained 
from other research studies. SI is representative of the underlying metabolic condition of the whole body, 
capturing patient-specific deviation from model population parameters. A previous study has shown to be 
relatively independent of both exogenous insulin and exogenous nutrition, allowing it to be used to compute 
the likely BG response to treatments other than those administered clinically [18]. To generate virtual 
patients, clinical data, comprising of BG measurements and insulin and/or nutrition inputs, is used with 
mathematical model to identify a model-based profile for each patient. These profiles, are addressed as 
virtual patients and can be used to simulate the response to a new or modified set of insulin and/or nutrition 
inputs [21], and using any type of protocol to generate simulated blood glucose outcomes. 
 
2.3.   Analysis by Virtual Simulation  
Different glycemic control protocols can be tested, virtually assessing likely BG outcomes in 
individual patients and across a cohort in a simulation. BG outcomes are a function of  , its variability, and 
the protocol that normally includes the chosen BG target range. Dickson et al. [19] have proven that this 
method is generalizable to any patient and with respect to several protocols. The virtual patient and virtual 
simulation framework are illustrated in Figure 2. If the virtual trial is generalizable, a proposed simulation-
based analysis comparing outcomes for different target ranges with the STAR protocol might give the 
favorable target ranges. Five target ranges are used in this analysis (4.0–6.0, 4.4–8.0, 6.0–8.0, 6.0–10.0, and 
8.0–10.0 mmol/L). The 4.4–8.0 mmol/L range is the default target range for the STAR protocol, and the 
other four are the target ranges used by 88% of Malaysian governmental hospitals. While the 4.4–8.0 mmol/L 
range is not used with any patient in Malaysia, this target range was included to allow comparison with the 
Christchurch, Gyulà, and Liege cohorts [17], [22-24].  
 
 
 
 
Figure 2. Virtual patient generation and virtual simulation framework. The image is retrieved from [19] 
 
 
The results are presented as percentage of time BG measurements are at certain BG levels: for 
example, a BG level of >10.0 mmol/L (limit of hyperglycemia), BG within the normoglycemia range, a BG 
level between 6–10 mmol/L, a BG level of 4.4–8.0 mmol/L, a BG level of <4.0 mmol/L (limit of mild 
hypoglycemia), and a BG level of <2.2 mmol/L (limit of severe hypoglycemia). The Mann–Whitney rank-
sum test was then used to compare the results from the two cohorts. This non-parametric statistic was chosen 
because of the typically skewed distributions of BG, insulin doses, and other data. P values of <0.05 were 
considered statistically significant. 
The virtual trial can also be used to perform self-simulation to test for model errors or any un-
modeled non-compliance to a clinical implementation. Conceptually, testing a virtual patient on the same 
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protocol that clinically produced the data should return the same BG data used to generate it, but with 
differences due to fitting error or in clinically following the protocol recommendation. Self-simulation was 
performed in the cohort that underwent the STAR pilot trial. 
 
2.4.   Patient Data and Applied Insulin Therapy 
IIUM patients treated using the STAR protocol were recruited from January 1 to November 5, 2017. 
The data comprised 27 episodes of 16 patients with a minimum of 24 h of control using the STAR protocol. 
This protocol recommended both insulin and nutrition doses, requiring hourly or three-hourly measurements 
of BG when outside or within the set target range, respectively. The starting criterion was two BG 
measurements of >10 mmol/L within a 1 hour period, and the goal was to control BG level within 6.0–10.0 
mmol/L with a 5% risk of BG level of <4.0 mmol/L (72 mg/dL) for each intervention. Contrary to 
availability of nutrition recommendation in the STAR control, IIUM administered intravenous-infusion 
insulin only therapy. When clinical opinion has determined that a patient is stable and insulin treatment 
should end or more than 5 hours has elapsed between treatment, STAR was stopped. Additionally, in this 
ICU, the stopping criteria was when the BG is within target range at insulin of 0.5 U/hr for two hours. A 
comparison of the clinical results with a simulated 6.0–10.0 mmol/L will present the self-simulation analysis. 
A total of 210 patient data with episodes for a minimum of 24 h were included in the second cohort 
from HTAA. The standard of glycemic control was based on the sliding scale method, dosing insulin based 
on the patient’s BG level and previous insulin dose, with the final target range of 4.0–6.0 mmol/L. The 
insulin rate was adjusted based on the current and previous BG level and the current insulin infusion rate, and 
the intervention was started when patients reached a BG level of at least 10 mmol/L for about 1 hour. BG 
was initially monitored hourly until it was within the target range for 2 hour and was then monitored every 4 
hour. Soluble insulin was used for continuous intravenous insulin infusion. This approach to control was 
limited by the inability to reduce the insulin infusion rates until BG was within the target range [25]. 
Both cohorts were based in Kuantan, Malaysia. Enteral and parenteral nutrition were used in both 
ICUs, although enteral therapy alone was used in most cases. Ultimately, the decision was made by the 
clinical staff, but the guideline recommends a target energy intake of 25 kcal/kg/day and at least 1.2–1.5 
g/kg/day of protein, adjusting the energy intake as per the severity and type of illness.  
 
 
3. RESULTS 
4.1   IIUM Results 
The results for IIUM cohort is summarized by whole cohort statistics in Table 1. The median and 
IQR nutrition rates reported in the table are distinguished per clinical and simulated target ranges results. 
STAR clinical outcomes using 1-3 hourly interventions averaging 1 measurement every ~1.27 hours. For 
virtual simulations, the average ranges from 1 measurement every ~0.99 to 1.44 hours. If we focus on the 
self-simulation cohort of 6.0–10.0 mmol/L, the difference of averaged 0.17 hours with clinical trial is largely 
gained through the number of BG measurements instead of the total hours on therapy. This result hints the 
non-compliance on nurses’ intervention on insulin treatment recommendation. Nurses seemed to introduce 
more insulins as compared to what were recommended. 
The median insulin rate in the clinical trial was 1.7 U/h and the median dextrose rate was 5.4 g/h. In 
the simulation cohorts, the highest insulin rate was in the 4.0–6.0 mmol/L target range (5.5 U/h), although the 
dextrose rate was the lowest (1.9 g/h). Surprisingly, there was a 0.0 U/h median insulin rate in the 8.0–10.0 
mmol/L simulation, whereas the dextrose rate was higher (4.9 g/h) and closest to that in the clinical trials. 
Except for the 8.0–10.0 mmol/L simulation, the maximum per-patient insulin rate was consistent across 
cohorts (median 8.0 U/h). Thus, the STAR protocol is flexible enough to control ranges of insulin and 
dextrose doses based on a patient’s SI and the therapeutic target, while considering safety and daily caloric 
requirements. 
Notably, in the BG level performances, clinical trial resulted with the second highest BG mean after 
the 8.0–10.0 mmol/L simulation with 8.6%. Between the simulations, 4.0–6.0 range scores the lowest BG 
mean (6.2%), and 6.0–10.0 mmol/L range recorded a lower BG mean than clinical's, with 7.80 mmol/L. In 
term of performance in given targeted ranges, for 6.0–10.0 mmol/L, the clinical trial resulted in 62.44% and 
its simulation is higher at 74.86%. 4.4–8.0, 4.0 –6.0, 6.0–8.0 and 8.0–10.0 mmol/L each performed with 
67.65%, 38.77%, 71.61% and 46.61% respectively. Further analysis was done on the performance over 
hyper- and hypoglycemia limits. The lowest and tighter target range of 4.0–6.0 derived the lowest percentage 
of hyperglycemia (9.93%) while the highest naturally came from the highest target range of 8.0–10.0 (28.25 
%). For mild hypoglycemia, STAR clinical and simulations assured the less than 5% limit, except for the 
4.0–6.0 simulation (5.87%). Severe hypoglycemia percentages ranges from 0.07 to 0.14 
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Table 1. IIUM and HTAA Cohorts Glycemic Control Results 
Performance and safety 
statistics for 
 IIUM cohort 
Clinical trial 
STAR virtual simulations 
4.4–8.0 4.0–6.0 6.0–8.0 6.0–10.0 8.0–10.0 
No. of patients (Male) 16(11) 
No. of episodes 27 
Number of BG measurements 1070 998 1148 1362 943 1206 
Total no. of hours 1361 1358 1353 1343 1357 1350 
Average measurement interval 1.27 1.36 1.18 0.99 1.44 1.33 
Insulin rate (U/hr): Median 
[IQR] 
1.7 [0.4–
3.4] 
4.0 [2.0–6.5] 5.5 [2.0–8.0] 2.0 [0.0–4.0] 2.0 [0.0–3.5] 0.0 [0.0–1.0 
Max Insulin rate (U/hr): 
Median [IQR] 
8.0 [5.8–
8.0] 
8.0 [8.8–8.0] 8.0 [8.0–8.0] 8.0 [8.0–8.0] 8.0 [6.3–8.0] 6.0 [5.3–6.0] 
Dextrose rate (g/hr): Median 
[IQR] 
5.4 [2.6–
5.9] 
2.6 [0.0–5.2] 1.9 [0.0–3.9] 3.9 [0.0–6.5] 3.9 [0.0–6.6] 4.9 [0.0–6.6] 
Dextrose rate: (% goal)) NA  39.7 [0.0–
79.5]  
29.8 [0.0–
59.6]  
59.6 [0.0–6.5]  59.6 [0.0–
100.0]  
74.5 [0.0–
100.0] 
Mean BG (mmol/L) 8.60 6.80 6.20 7.50 7.80 9.00 
%BG >10 mmol/L 28.67 11.26 9.93 14.60 15.32 28.25 
%BG within 4.4–8.0 mmol/L 36.25 67.65 65.80 60.00 52.24 24.47 
%BG within 6.0–10.0 mmol/L 62.44  58.41 45.43 71.61 74.86 68.43 
%BG within 4.0–10.0 mmol/L 70.67 84.99 84.20 84.09 83.81 71.02 
%BG <4.0 mmol/L 0.66 3.75 5.87 1.31 0.87 0.73 
%BG <2.2 mmol/L 0.07 0.22 0.58 0.36 0.14 0.07 
Performance and safety 
statistics for  
HTAA cohort 
Clinical trial 
(SS 4.0–
6.0) 
STAR VIRTUAL SIMULATIONS 
4.4–8.0 4.0–6.0 6.0–8.0 6.0–10.0 8.0–10.0 
No. of patients (Male) 210 (119) 
No. of episodes 210 
Number of BG measurements 13011 17580 21385 26675 17070 22775 
Total no. of hours 26727 26610 26573 26518   26619 26560 
Average measurement interval 2.05 1.51 1.24 0.99 1.56 1.17 
Insulin rate (U/hr): Median 
[IQR] 
2.0 [1.0–
3.0] 
5.0 [2.0–8.0] 6.0 [3.0–8.0] 2.5 [0.0–6.0] 2.0 [0.0–4.0] 0.0 [0.0–2.0] 
Max Insulin rate (U/hr): 
Median [IQR] 
4.0 [3.0–
5.5] 
8.0 [8.0–8.0]  8.0 [8.0–8.0] 8.0 [8.0–8.0] 8.0 [8.0–8.0] 6.0 [5.5–8.0] 
Dextrose rate (g/hr): Median 
[IQR] 
4.1 [2.6–
6.0] 
3.9 [1.9–6.5] 1.9 [1.9–4.5] 4.6 [1.9–6.6] 5.5 [1.9–6.6] 6.5 [3.9–6.6] 
Dextrose rate: (% goal)) NA 59.6 [29.8–
99.3] 
29.8 [29.8–
69.5] 
70.8 [29.8–
100.0] 
84.4 [29.8–
100.0] 
100 [59.6–
100.0] 
Mean BG (mmol/L) 8.6 6.9 6.3 7.6 8.3 9.6 
%BG >10 mmol/L 31.26 14.69 12.89 19.89 23.40 40.32 
%BG within 4.4–8.0 mmol/L 40.62 63.16 64.94 56.05 43.76 19.14 
%BG within 6.0–10.0 mmol/L 56.46 56.11 43.26 71.35 70.15 57.52 
%BG within 4.0–10.0 mmol/L 67.79 69.31 83.44 79.68 91.3 59.60 
%BG <4.0 mmol/L 0.95 2.16 3.67 0.43 0.40 0.08 
%BG <2.2 mmol/L 0.04 0.06 0.11 0.02 0.01 0.00 
 
 
3.2.  HTAA results 
The results for the HTAA cohort are also summarized in Table 1. The cohort was 13 times bigger 
than the IIUM cohort, but the acquired data (hours and BG measurements) were 20 times bigger. The IIUM 
cohort tended to have shorter episodes because the STAR protocol led to a quick stabilization of glycemic 
levels. The clinical trial used an insulin sliding scale therapy and set a BG target range of 4.0–6.0 mmol/L, 
with the HTAA profiles used to assess the performances of simulations of target ranges compared with the 
IIUM cohort. In terms of averaged 1 over hours of BG intervention, similar to IIUM virtual simulations, the 
larger target range of 4.4–8.0 and 6.0–10.0 mmol/L have the higher 1 over average of 1.51 and 1.56 hour 
measurements. The simulated values when compared with the clinical data (1 over 2.05 hours) however 
shows that STAR protocol tends to introduce more clinical intervention. 
The clinical data showed the median insulin rate and per-patient max insulin rate to be similar to the 
6.0–8.0 and 6.0 –10.0 simulations but half of those simulated using lower target ranges simulation (4.0–6.0 
and 4.4–8.0). The median dextrose rates are however vary without specific pattern. Similarly to the IIUM 
cohort analysis, Simulation from target range of 4.0–6.0 mmol/L introduced the highest median insulin rate 
and simulation 8.0–10.0 introduced the highest dextrose rate. Per-patient maximum insulin rate records the 
same consistency at 8.0 and 6.0 U/hr. The glycemic control protocol applied in HTAA organizes the nutrition 
therapy separated from insulin infusion, it may introduces differences to the variations if compared to the 
IIUM's cohort. However from the similarities of results thus far, positively a comparison of BG performance 
can be done with the IIUM results. 
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To consolidate our findings, the Mann–Whitney test was conducted for the comparison of the IIUM 
and HTAA cohorts (Table 2). The analysis was based on both the original protocol and the virtual simulation 
using the representative target range of 6.0–10.0 mmol/L.  The Mann–Whitney test was used to assess the 
two-tailed distribution of significant differences between the two cohorts. None of the variables, including 
the mean BG performance, were significantly different. The mean BG level for the original protocol and 
virtual simulation produced a P-value of 0.051, which is close to the significance threshold. 
 
 
Table 2. Comparison of the IIUM and HTAA Cohorts at the 6.0 – 10.0 mmol/L Target Range using the 
Mann-Whitney test 
Performance and safety statistics due to  
6.0–10.0 mmol/L target range 
IIUM cohort HTAA cohort Mann Whitney test 
Original protocol 
Insulin rate (U/hr): median [IQR]  1.7 [0.4–3.4] 2.0 [1.0–3.0] P: 0.80 
Dextrose rate (g/hr): Median [IQR]  5.4 [2.6–5.9] 4.1 [2.6–6.0] P: 0.90 
Mean BG (mmol/L)  8.76 8.58 P: 0.14 
Mean BG (mmol/L)  8.60 8.60 P: 0.05 
Virtual simulation 
Insulin rate (U/hr): median [IQR] 2.0 [0.0–3.5] 2.0 [0.0–4.0] P: 0.80 
Dextrose rate (g/hr): Median [IQR] 3.9 [0.0–6.6] 5.5 [1.9–6.6] P: 0.906 
Mean BG (mmol/L) 7.97 8.39 P: 0.14 
Mean BG (mmol/L)  7.80 8.30 P: 0.05 
 
 
In terms of BG performance, the clinical trials and simulations produced similar mean BG values. 
Between the simulations, the 4.0–6.0 mmol/L range produced the lowest mean BG. Performance in given 
targeted ranges was the highest for the 6.0–10.0 mmol/L at 70.15%, followed by the 4.4–8.0 mmol/L 
simulation at 63.16%. The other simulations had performances of <50%, presumably because they used 
stricter target ranges. The performance values inside the normoglycemic range (4.4–10.0 mmol/L) varied 
from 59.60% to 83.44%. The simulation records in the HTAA cohort for 4.0–6.0 mmol/L had the lowest 
mean value of 6.30% and the lowest percentage of BG of >10 mmol/L, but also had the highest number of 
patients with severe hypoglycemia (0.11%). Indeed, the percentage of patients with severe hypoglycemia was 
more than double that in the clinical trial (0.04%), which shared the same target range, but used a sliding 
scale. The results indicated that all ranges were safe (<5% with mild hypoglycemia). Moreover, the 8.0–10.0 
mmol/L simulation resulted in no cases of severe hypoglycemia in the HTAA cohort and very few cases in 
the IIUM cohort (0.07%). 
 
 
4. DISCUSSION 
To present the performance of each target range simulation, the results from the cohort analysis are 
summarized in Figure 3. The primary y-axis shows the performance for each range (different colored bars) 
with the percentages of hyperglycemia (red lines). The secondary y-axis shows the percentages of 
hypoglycemia at the two limits (black lines and dashes). The normoglycemia range is also displayed in the 
primary y-axis (green bars). To highlight the performance per simulation according to the given target range, 
the colored bars are denoted with a line pattern. Comparing the cohorts, two conclusions can be drawn. First, 
if the STAR protocol is used with 100% compliance, performance can be improved using the proposed 6.0–
10.0 mmol/L target range. This is consistent with the range used in the pilot trial at IIUM, and it benefits 
from minimizing the risks of hyperglycemia and hypoglycemia. It also provided the highest simulated 
performance in both the IIUM and HTAA cohorts. 
Second, virtual simulations in the Malaysian patients showed that the 6.0–8.0 and 6.0–10.0 mmol/L 
ranges optimized the rate of hyperglycemic and hypoglycemic events. While the performance of the 6.0–8.0 
mmol/L simulation was low, the time its patients spend within the 4.4–10.0 mmol/L range was comparable to 
that within the 6.0–10.0 mmol/L simulation. To decide the better option, a comparison was done using the 
introduced insulin, introduced dextrose, targeted dextrose rate achieved, and measurement intervals. The first 
three variables gave similar values, and only the measurement interval produced a difference. The 6.0–10.0 
mmol/L simulation averaged 1.44 and 1.56 number of measurements every hour in the IIUM and HTAA 
cohorts, respectively, indicating fewer interventions, thus less workloads. 
Focusing solely on the performance of the 4.4–8.0 mmol/L target range in the IIUM and HTAA 
cohorts hinted at the ability of the STAR protocol to achieve glycemic control with acceptable rate of 
hyperglycemic and hypoglycemic events. However, their respective simulated values of 67.65% and 63.16% 
were very low compared with the virtual trial results of Dickson et al. [19], who reported a minimum of 
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81.0% of time spent in the 4.4–8.0 mmol/L target range among patients in the Gyulà and New Zealand 
cohorts. The result is, however, similar to that in the Belgian report of patients who underwent insulin control 
with the sliding scale method. This finding supports the hypothesis that Malaysian cohorts have different rate 
of metabolism that requires them to have different target ranges to achieve optimal glycemic control, both in 
general and when using the STAR protocol. Although this analysis was only statistical, we conclude that 
Malaysian patients will gain most benefit from the target range of 6.0–10.0 mmol/L in terms of controlling 
hyperglycemia, preventing hypoglycemia, and reduced workload. Currently, only 50% of government and 
research university hospitals use this target range, which we believe should be used for future STAR trials in 
these hospitals. 
 
 
 
 
 
Figure 3. Interpolated IIUM and HTAA cohort statistics 
 
 
Finally, a limitation of our simulations was that they relied on virtual patients drawn from two ICUs 
from the same region in Malaysia. These patients may different underlying metabolisms from other 
Malaysian patients, which would have affected the generalizability to all Malaysians. However, this study 
provides relevant data and should prompt further investigation into these demographic factors, such as 
ethnicity, which may affect the performance of the STAR protocol in Indonesia, India, and China, as 
Malaysian are generally constituted of Malays, Indian and Chinese. 
 
 
5. CONCLUSION 
In this research, we have presented an analysis of virtual patients from two different ICUs using a 
model-based virtual trial framework in which BG target ranges were varied and compared with each other. 
Patients were included to test the performance and safety of the STAR framework in Malaysian patients, 
seeking to extend its generalizability and to identify the favorable target range. We showed that the non-
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default STAR target range of 6.0–10.0 mmol/L had the best balance of performance, safety, and frequency of 
nursing interventions among the target ranges tested. This result is encouraging as it is consistent with the 
target range recommended for achieving glycemic control in other scenarios with respect to Malaysian 
patients. 
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